Abstract 95P
Background
Previous studies have shown that triple-negative breast cancer (TNBC) owned a higher degree of malignancy clinically, and its tumor progression rate was much higher than that of other types of breast cancer. TNBC is more common in young women, with rapid tumor growth, lack of effective treatment and poor prognosis. Therefore, it is urgent to discover new molecular targets for the treatment and prediction of TNBC progression and prognosis.
Methods
We analyzed the differences between 13 TNBC cell lines and 2 normal breast cell lines. Moreover, RNA-sequencing techniquewas used to determine the level of differential expressed mRNAs in tumor samples from TNBC patients (n=55) compared with non-TNBC patients [Her2 positive (n=39), Lumina A (n=29), Lumina B (n=30), Healthy control (n=11)]. Then, we used qRT-PCR to confirm the differential-expressed mRNAs in breast cancer cell lines. Furthermore, we used the survival data of in the TCGA database to predict the effect of theses mRNAs on the prognosis of TNBC patients.
Results
We analyzed the microarray of different cell lines and found that 1709 differentially-expressed mRNAs in TNBC cell lines compared with normal breast cell lines. Moreover, we profiled the mRNAs in the tumor samples from TNBC patients and non-TNBC patients and detected: 1098 differentially-expressed mRNAs in TNBC compared with healthy control, 209 differentially-expressed mRNAs in TNBC compared with Her2 positive, 659 differentially-expressed mRNAs in TNBC compared with Lumina A and 361 differentially-expressed mRNAs in TNBC compared with Lumina B. Comprehensive analysis of the above results, we found 6 mRNAs (NR2F1, TFF3, COL10A1, NTN4, MMP12, SFRP1) dysregulated in TNBC cell lins and tissue. Kaplan-Meier plots showed the lower expression of SFRP1 and the higher expression of COL10A1 was connected to poor prognosis in TNBC patients from TCGA database.
Conclusions
The expression of NR2F1, TFF3, COL10A1, NTN4, MMP12, SFRP1 were found significantly dysregulated in TNBC cells and tumor tissues. Moreover, the expression level of SFRP1 and COL10A1 are related to the prognosis of TNBC patients. Therefore, this study provides a fresh perspective on novel therapeutic targets and potential biomarkers for TNBC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sujin Yang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.